Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

Ruijie Liu,Wenfang Wang,Wenfeng Li
DOI: https://doi.org/10.18632/aging.205707
2024-10-11
Aging
Abstract:Coronary microembolization (CME)-induced inflammatory response and cardiomyocyte apoptosis are the main contributors to CME-associated myocardial dysfunction. Bezafibrate, a peroxisome proliferator-activated receptors (PPARs) agonist, has displayed various benefits in different types of diseases. However, it is unknown whether Bezafibrate possesses a protective effect in myocardial dysfunction against CME. In this study, we aimed to investigate the pharmacological function of Bezafibrate in...
cell biology,geriatrics & gerontology,gerontology
What problem does this paper attempt to address?